Cytokinetics

Braveheart files for IPO to support Hengrui-licensed cardio asset

Braveheart Bio isn’t letting Big Pharma take its freedom anytime soon as it aims for a Nasdaq listing to move its phase 3 cardiovascular drug forward.

Will Maddox Jul 15, 2026 1:40pm